RIP kinase

Receptor-interacting protein kinases; RIPK

RIP kinase

Related Products

Receptor-interacting protein (RIP) kinases are a group of threonine/serine protein kinases with a relatively conserved kinase domain but distinct non-kinase regions. There are seven members of the RIPK family, RIPK1-7, some of which have emerged as critical effectors of immunity to infection with a diverse array of bacterial, viral, and protozoal pathogens.

RIP kinases are cellular signaling molecules that are critical for homeostatic signaling in both communicable and non-communicable disease processes. RIPK1, RIPK2, RIPK3 and RIPK7 have emerged as key mediators of intracellular signal transduction including inflammation, autophagy and programmed cell death, and are thus essential for the early control of many diverse pathogenic organisms.

RIP kinase Related Products (98)
Recombinant Proteins (2)
Antibodies (1)

By Effects:	Inhibitors (93) Activators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-122909

GSK2593074A	Inhibitor	98.67%
GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3.

HY-114349

HS-1371	Inhibitor	99.89%
HS-1371 is a potent and ATP-competitive receptor-interacting protein kinase 3 (RIP3) inhibitor with an IC₅₀ of 20.8 nM.

HY-111946

GSK3145095	Inhibitor	99.39%
GSK3145095 is a RIP1 kinase inhibitor with an IC₅₀ of 6.3 nM .

HY-114371

Eclitasertib	Inhibitor	99.92%
Eclitasertib (DNL-758) is a potent receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC₅₀ of <1 µΜ (From patent WO2017136727A2, example 42).

HY-138779

ICCB-19 hydrochloride	Inhibitor	99.24%
ICCB-19 hydrochloride is a TRADD (TNFRSF1A associated via death domain) inhibitor. ICCB-19 hydrochloride binds with N-terminal domain of TRADD (TRADD-N), disrupting its binding to both TRADD-C and TRAF2. ICCB-19 hydrochloride is indirect inhibitor of RIPK1 kinase activity. ICCB-19 hydrochloride effectively induces autophagy and the degradation of long-lived proteins.

HY-131064

RIPK3-IN-1	Inhibitor	99.19%
RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC₅₀ of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC₅₀s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC₅₀ of 1.1 μM.

HY-111870

PROTAC RIPK degrader-6	Inhibitor	99.97%
PROTAC RIPK degrader-6 (example 1) is a Cereblon-based PROTAC targeting RIP Kinase degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder.

HY-19764

GSK2983559 active metabolite	Inhibitor	98.87%
GSK2983559 active metabolite is an active metabolite of GSK2983559. GSK2983559 active metabolite is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.

HY-19628

OD36	Inhibitor	98.70%
OD36 is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with K_Ds of 37 nM.

HY-107978

RIPK-IN-4	Inhibitor	99.71%
RIPK-IN-4 is a potent and selective RIPK2 inhibitor with excellent oral bioavailability, and has an IC₅₀ of 3 nM.

HY-128348

PK68	Inhibitor	99.92%
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC₅₀ of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis.

HY-112038

GSK2983559 free acid	Inhibitor	99.90%
GSK2983559 free acid (compound 3) is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 free acid can block many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples.

HY-111409

RIP1 kinase inhibitor 1	Inhibitor	99.96%
RIP1 kinase inhibitor 1 (compound 22) is a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor (pK_i=9.04).

HY-100131

GSK481	Inhibitor	98.57%
GSK481 is a highly potent, selective, and specific receptor interacting protein 1 (RIP1) kinase inhibitor with an IC₅₀ of 1.3 nM, which inhibits Ser¹⁶⁶ phosphorylation in wild-type human RIP1 (IC₅₀=2.8 nM). GSK481 also exhibits excellent translation in the U937 cellular assay with an IC₅₀ of 10 nM.

HY-119933

RIPK1-IN-7	Inhibitor	98.67%
RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a K_d of 4 nM and an enzymatic IC₅₀ of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model.

HY-19761

RIP2 kinase inhibitor 2	Inhibitor	99.16%
RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.

HY-132203

Necrostatin-34	Inhibitor	98.75%
Necrostatin-34 (Nec-34), a RIPK1 kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.

HY-135826

Necroptosis-IN-1	Inhibitor	98.39%
Necroptosis-IN-1, an analog of Necrostatin-1, is a potent necroptosis inhibitor. Necroptosis-IN-1 is a RIPK inhibitor.

HY-124546

Necrostatin-5	Inhibitor	98.43%
Necrostatin-5 (Nec-5) is a potent necroptosis inhibitor with an EC₅₀ value of 0.24 µM. Necrostatin-5 also is a RIP1 inhibitor. Necrostatin-5 shows cardioprotective effects.

HY-14622B

Necrostatin 2 S enantiomer	Inhibitor	99.70%
Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2.

Name
Email *

	Sorry, but the email address you supplied was invalid.

RIP kinase

RIP kinase

RIP kinase Related Products (98)

Recombinant Proteins (2)

Antibodies (1)

RIP kinase Related Products (98):